Biogen Inc's Corporate Customers have recorded an advance in their cost of revenue by 8.42 % in the 1 quarter 2026 year on year, sequentially costs of revenue were trimmed by -5.98 %. During the corresponding time, Biogen Inc recorded a revenue increase by 1.93 % year on year, sequentially revenue grew by 8.7 %. While revenue at the Biogen Inc 's corporate clients recorded rose by 5.5 % year on year, sequentially revenue fell by -2.35 %.
Biogen Inc's Customers have recorded an advance in their cost of revenue by 8.42 % in the 1 quarter 2026 year on year, sequentially costs of revenue were trimmed by -5.98 %, for the same period Biogen Inc recorded revenue increase by 1.93 % year on year, sequentially revenue grew by 8.7 %.
Biogen Inc's Comment on Sales, Marketing and Customers
We focus our sales and marketing efforts on specialist physicians in private
practice or at major medical centers. We use customary pharmaceutical company
practices to market our products and to educate physicians, such as sales representatives
calling on individual physicians, advertisements, professional symposia, direct
mail, public relations and other methods. We provide customer service and other
related programs for our products, such as disease and product-specific websites,
insurance research services and order, delivery and fulfillment services. We have
also established programs in the U.S. which provide qualified uninsured or underinsured
patients with marketed products at no or reduced charge, based on specific eligibility
criteria. Additional information about our sales, marketing and distribution efforts
for our marketed products is set forth below.
AVONEX
We continue to focus our marketing and sales activities on maximizing the potential
of AVONEX in the U.S. and the rest of world in the face of increased competition,
including from our own products and products of our competitors. The principal
markets for AVONEX are the U.S., Germany, France, Italy and the United Kingdom.
In the U.S., Canada, Brazil, Argentina, Australia, Japan and most of the major
countries of the E.U., we market and sell AVONEX through our own sales forces
and marketing groups and distribute AVONEX principally through wholesale distributors
of pharmaceutical products, mail order specialty distributors or shipping service
providers. In other countries, we sell AVONEX to distribution partners who are
then responsible for most marketing and distribution activities.
TYSABRI
The principal markets for TYSABRI are the U.S., the United Kingdom, France,
Germany, Italy and Spain. Following the completion of our acquisition of 100%
of the rights to TYSABRI from Elan in April 2013, we are solely responsible
for the marketing and sale of TYSABRI for MS in the U.S. and the rest of world.
We use a combination of our own sales force and marketing group and third party
service providers for our marketing and distribution of TYSABRI.
TECFIDERA
The principal market for TECFIDERA is the U.S. and the E.U. In the U.S., E.U.,
Canada and Australia, we market and sell TECFIDERA through our own sales forces
and marketing groups and distribute TECFIDERA principally through wholesale
distributors of pharmaceutical products, mail order specialty distributors or
shipping service providers.
RITUXAN and GAZYVA
The Roche Group and its sub-licensees market and sell RITUXAN worldwide. In
the U.S., we collaborate with Genentech on the development and commercialization
of RITUXAN, but Genentech maintains sole responsibility for the U.S. sales and
marketing efforts related to RITUXAN. RITUXAN is generally sold to wholesalers,
specialty distributors and directly to hospital pharmacies.
Pursuant to our agreement with Genentech, the Roche Group and its sub-licensees
will maintain sole responsibility for the development, manufacturing and commercialization
of GAZYVA in the U.S.
FAMPYRA
We market and sell FAMPYRA in major markets outside the U.S., such as France,
Germany, Spain and Canada, through our own sales forces and marketing groups
and distribute FAMPYRA in those markets principally through wholesale distributors
of pharmaceutical products. In other countries outside the U.S., we sell FAMPYRA
to distribution partners who are then responsible for most marketing and distribution
activities. Our commercialization rights do not include the U.S. market.
FUMADERM
FUMADERM is marketed only in Germany, through our own sales force and marketing
group.
Major Law Firms Alert Investors: Class Action Lawsuits Against Biogen, Charge Enterprises, and Fastly Deadlines LoomingNew York, June 9, 2024 Bragar Eagel and Squire, P.C., a nationally-recognized shareholder rights law firm, has formally reminded investors that class action lawsuits have been filed against three prominent corporations: Biogen Inc. (NASDAQ: BIIB), Charge Enterprises (NASDAQ: CRGEQ), and Fastly, Inc. (NYSE: FSLY). Investors who have suffered losses are urged to come forward and petition the court to serve as lead plaintiff before impending deadlines. Biogen Inc. (NASDAQ: BIIB)On May 28, 2024, Bragar Eagel and Squire, P.C. announced the initiation of a class action lawsuit against Biogen In...
Biogen Inc., a leading biopharmaceutical company, is currently facing a class action lawsuit and a decline in revenue. The company and certain officers have been named as defendants in the lawsuit, which was filed in the United States District Court for the District of Colorado. Shareholders who suffered losses on their investments in Biogen Inc. between February 3, 2022, and February 13, 2024, are seeking damages for violations of federal securities laws.In addition to the legal challenges, Biogen Inc. has also experienced a deterioration in revenue. In the first quarter of 2024, the company s corporate customers saw a 7.38% increase in their cost of revenue, while Biogen Inc. s revenue fell by 7% year on y...
: This article outlines the collaboration between Biogen Inc. and Delta Flight Products to enhance air travel accessibility for passengers with reduced mobility. Additionally, it examines Biogen s financial performance in Q1 2024, highlighting trends in revenue, costs, and corporate customer performance. On June 3, 2024, Biogen Inc. (Nasdaq: BIIB) and Delta Flight Products (DFP) announced a collaborative effort aimed at improving air travel for passengers with reduced mobility. This initiative addresses the needs of approximately 5.5 million individuals in the United States who rely on wheelchairs for mobility. This article delves into the implications of this collaboration and examines Biogen s recent fina...
Biogen Inc., a leading biopharmaceutical company, has recently announced significant interim biomarker data that further supports the potential benefits of SPINRAZA (nusinersen) in infants and toddlers with spinal muscular atrophy (SMA) who have unmet clinical needs after gene therapy. This breakthrough therapy has shown promise in addressing axonal injury and neurodegeneration, offering hope to patients and their families.In the Phase 4 RESPOND study led by Biogen, interim 6-month biomarker data from the initial 29 participants have demonstrated positive clinical outcomes and safety following treatment with SPINRAZA. The study aims to evaluate the effectiveness of SPINRAZA over a 2-year period in infants an...
Biogen Receives European Commission Approval for SKYCLARYS (omaveloxolone) as the First Treatment for Friedreich s Ataxia, While ZURZUVAE (zuranolone) CIV Offers a Landmark Oral Treatment for Postpartum Depression in the U.S.Biogen, a leading biotechnology company, has recently achieved a significant advance in the field of neurodegenerative diseases with the European Commission s approval of SKYCLARYS (omaveloxolone) as the first therapy for Friedreich s Ataxia (FA) in adults and adolescents aged 16 years and older. In addition, Biogen has also made significant progress in women s mental health by making ZURZUVAE (zuranolone) CIV, a groundbreaking oral treatment for Postpartum Depression (PPD), available in...
Revocation of Centralized Marketing Authorizations for TECFIDERA Generics: A Blow to Biogen Inc. and its Corporate Customers CAMBRIDGE, Mass., Dec. 19, 2023 - Biogen Inc. (Nasdaq: BIIB) has recently faced a significant setback as the European Commission revoked the centralized marketing authorizations for generic versions of its flagship product TECFIDERA (dimethyl fumarate). This decision affects multiple pharmaceutical companies, including Accord, Mylan, Neuraxpharm, Polpharma, and Teva, who held these authorizations. In a related development, Biogen Inc. s corporate customers have recorded a 2.15% increase in their cost of revenue in the third quarter of 2023 compared to the previous year. Sequent...
Biogen Inc’s Comment on Sales, Marketing and Customers
We focus our sales and marketing efforts on specialist physicians in private
practice or at major medical centers. We use customary pharmaceutical company
practices to market our products and to educate physicians, such as sales representatives
calling on individual physicians, advertisements, professional symposia, direct
mail, public relations and other methods. We provide customer service and other
related programs for our products, such as disease and product-specific websites,
insurance research services and order, delivery and fulfillment services. We have
also established programs in the U.S. which provide qualified uninsured or underinsured
patients with marketed products at no or reduced charge, based on specific eligibility
criteria. Additional information about our sales, marketing and distribution efforts
for our marketed products is set forth below.
AVONEX
We continue to focus our marketing and sales activities on maximizing the potential
of AVONEX in the U.S. and the rest of world in the face of increased competition,
including from our own products and products of our competitors. The principal
markets for AVONEX are the U.S., Germany, France, Italy and the United Kingdom.
In the U.S., Canada, Brazil, Argentina, Australia, Japan and most of the major
countries of the E.U., we market and sell AVONEX through our own sales forces
and marketing groups and distribute AVONEX principally through wholesale distributors
of pharmaceutical products, mail order specialty distributors or shipping service
providers. In other countries, we sell AVONEX to distribution partners who are
then responsible for most marketing and distribution activities.
TYSABRI
The principal markets for TYSABRI are the U.S., the United Kingdom, France,
Germany, Italy and Spain. Following the completion of our acquisition of 100%
of the rights to TYSABRI from Elan in April 2013, we are solely responsible
for the marketing and sale of TYSABRI for MS in the U.S. and the rest of world.
We use a combination of our own sales force and marketing group and third party
service providers for our marketing and distribution of TYSABRI.
TECFIDERA
The principal market for TECFIDERA is the U.S. and the E.U. In the U.S., E.U.,
Canada and Australia, we market and sell TECFIDERA through our own sales forces
and marketing groups and distribute TECFIDERA principally through wholesale
distributors of pharmaceutical products, mail order specialty distributors or
shipping service providers.
RITUXAN and GAZYVA
The Roche Group and its sub-licensees market and sell RITUXAN worldwide. In
the U.S., we collaborate with Genentech on the development and commercialization
of RITUXAN, but Genentech maintains sole responsibility for the U.S. sales and
marketing efforts related to RITUXAN. RITUXAN is generally sold to wholesalers,
specialty distributors and directly to hospital pharmacies.
Pursuant to our agreement with Genentech, the Roche Group and its sub-licensees
will maintain sole responsibility for the development, manufacturing and commercialization
of GAZYVA in the U.S.
FAMPYRA
We market and sell FAMPYRA in major markets outside the U.S., such as France,
Germany, Spain and Canada, through our own sales forces and marketing groups
and distribute FAMPYRA in those markets principally through wholesale distributors
of pharmaceutical products. In other countries outside the U.S., we sell FAMPYRA
to distribution partners who are then responsible for most marketing and distribution
activities. Our commercialization rights do not include the U.S. market.
FUMADERM
FUMADERM is marketed only in Germany, through our own sales force and marketing
group.
Sources:
Biogen Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Biogen Inc’s corporate clients.
For your research, we’ve provided 9 tables on Biogen Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
70.72 %
5.52 % 